Skip to main content
Figure 1 | BMC Public Health

Figure 1

From: Cost-effectiveness and cost utility analysis of three pneumococcal conjugate vaccines in children of Peru

Figure 1

One-way sensitivity analysis of ICERs. A: PHiD-CV vs no vaccine; B: PCV-13 vs no vaccine. Dashed line in A shows the ICER for PCV-13 vaccine and in B shows the ICER PHiD-CV vaccine. AOM, acute otitis media; CAP, community acquired pneumonia; CI, confidence interval; GP, general practitioner; ICER, incremental cost-effectiveness ratio; PCV-13, 13-valent pneumococcal conjugate vaccine; PHiD-CV, 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine.

Back to article page